Symbicort
E505484
COPD maintenance therapy
asthma maintenance therapy
combination drug
inhaler medication
prescription medication
Symbicort is a prescription inhaler medication that combines a corticosteroid and a long-acting bronchodilator to manage asthma and chronic obstructive pulmonary disease (COPD).
All labels observed (1)
| Label | Occurrences |
|---|---|
| Symbicort canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5248765 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Symbicort Context triple: [AstraZeneca, notableProduct, Symbicort]
-
A.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
B.
Singulair
Singulair is a prescription leukotriene receptor antagonist (montelukast) commonly used to prevent and manage asthma and allergy symptoms.
-
C.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Symbicort Target entity description: Symbicort is a prescription inhaler medication that combines a corticosteroid and a long-acting bronchodilator to manage asthma and chronic obstructive pulmonary disease (COPD).
-
A.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
B.
Singulair
Singulair is a prescription leukotriene receptor antagonist (montelukast) commonly used to prevent and manage asthma and allergy symptoms.
-
C.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
COPD maintenance therapy
ⓘ
asthma maintenance therapy ⓘ combination drug ⓘ inhaler medication ⓘ prescription medication ⓘ |
| abbreviation | budesonide/formoterol ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| containsComponent |
corticosteroid
ⓘ
long-acting beta2-adrenergic agonist ⓘ |
| hasActiveIngredient |
budesonide
NERFINISHED
ⓘ
formoterol fumarate dihydrate ⓘ |
| hasBrandName | Symbicort NERFINISHED ⓘ |
| hasCommonSideEffect |
cough
ⓘ
headache ⓘ hoarseness ⓘ oral candidiasis ⓘ throat irritation ⓘ |
| hasDosageForm | metered-dose inhaler ⓘ |
| hasGenericName | budesonide and formoterol fumarate dihydrate ⓘ |
| hasManufacturer | AstraZeneca NERFINISHED ⓘ |
| hasPharmacologicClass |
inhaled corticosteroid
ⓘ
long-acting beta2-agonist ⓘ |
| hasRegulatoryStatus | prescription only ⓘ |
| hasRoute | oral inhalation ⓘ |
| hasWarning |
immunosuppression due to corticosteroid component
ⓘ
potential adrenal suppression ⓘ risk of asthma-related death with LABA monotherapy ⓘ |
| improves |
COPD symptom control
ⓘ
asthma symptom control ⓘ lung function ⓘ |
| indicatedFor |
COPD with chronic bronchitis
ⓘ
asthma ⓘ chronic obstructive pulmonary disease ⓘ maintenance treatment of COPD ⓘ maintenance treatment of asthma ⓘ |
| mechanismOfAction |
causes bronchodilation via beta2-adrenergic receptor agonism
ⓘ
reduces airway inflammation via corticosteroid activity ⓘ |
| notIndicatedFor |
relief of acute bronchospasm
ⓘ
rescue treatment for sudden asthma attacks ⓘ |
| reduces |
COPD exacerbations
ⓘ
frequency of asthma exacerbations ⓘ |
| regulates |
airway inflammation
ⓘ
bronchial smooth muscle tone ⓘ |
| requires |
regular daily use for maintenance
ⓘ
rinsing mouth after use to reduce risk of oral thrush ⓘ |
| routeOfAdministration | inhalation ⓘ |
| usedWith | short-acting beta2-agonist rescue inhaler ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Symbicort Description of subject: Symbicort is a prescription inhaler medication that combines a corticosteroid and a long-acting bronchodilator to manage asthma and chronic obstructive pulmonary disease (COPD).
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.